MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

NCT05131997 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2022-07-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

AD-221

PO, Once daily(QD), 8 weeks

DRUG

AD-221A

PO, Once daily(QD), 8 weeks

DRUG

AD-221B

PO, Once daily(QD), 8 weeks

DRUG

AD-221C

PO, Once daily(QD), 8 weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Sang Hak Lee, M.D., Ph.D · Yonsei University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2022-06-08
Completion
2022-06-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131997 on ClinicalTrials.gov